SCHEMBL407668

SCHEMBL407668

Cc1ccccc1S(=O)(=O)NCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.61
CA9 Q16790 2/20 0.61
L3MBTL1 Q9Y468 3/20 0.60
CYP1A2 P05177 2/20 0.60
CYP3A4 P08684 1/20 0.60
ATM Q13315 1/20 0.60
KEAP1 Q14145 1/20 0.59
POLB P06746 1/20 0.57
NSD2 O96028 2/20 0.56
CYP2C19 P33261 1/20 0.56
OPRK1 P41145 1/20 0.55
CA2 P00918 1/20 0.55
CA7 P43166 1/20 0.55
CA14 Q9ULX7 1/20 0.55
LMNA P02545 1/20 0.54
SLC12A2 P55011 1/20 0.54
SLC12A5 Q9H2X9 1/20 0.54
BRD4 O60885 1/20 0.53
BRD2 P25440 1/20 0.53
BRD3 Q15059 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28578514 0.88 CA12 (0.56) CA12CA9L3MBTL1CYP1A2CYP3A4
SCHEMBL11174344 0.87 SMN1; SMN2 (0.69) L3MBTL1POLBNSD2LMNAALDH1A1
SCHEMBL14623888 0.87 CNR1 (0.58) CA12CA9OPRK1LMNASLC12A2
SCHEMBL30681710 0.85 LMNA (0.55) CA12CA9L3MBTL1CYP1A2CYP3A4
SCHEMBL7011026 0.83 TSHR (0.74) CYP1A2CYP3A4POLBCYP2C19ALDH1A1
SCHEMBL17101701 0.83 NR3C2 (0.48) CA12CA9L3MBTL1CYP1A2CYP3A4
SCHEMBL411161 0.83 SFRP1 (0.66) L3MBTL1POLBNSD2BRD4BRD2
SCHEMBL20100265 0.82 TSHR (0.54) L3MBTL1POLBALDH1A1
SCHEMBL1032718 0.81 KDM4E (0.60) CA12CA9L3MBTL1CYP1A2CYP3A4
SCHEMBL28113718 0.81 POLB (0.56) CA12CA9L3MBTL1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112047865-B Method for synthesizing N-alkyl sulfonamide in water 南京理工大学 2022-12-02 CN disclosed
CN-110832034-B Moisture-curable resin composition, adhesive for electronic component, and adhesive for display element 积水化学工业株式会社 2022-10-18 CN disclosed
US-11124482-B2 C-met modulators and methods of use EXELIXIS, INC. (US) 2021-09-21 US disclosed
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. 2021-08-19 US disclosed
CN-112047865-A Method for synthesizing N-alkyl sulfonamide in water 南京理工大学 2020-12-08 CN disclosed
US-20200331860-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2020-10-22 US disclosed
CN-110832034-A Moisture-curable resin composition, adhesive for electronic component, and adhesive for display element 积水化学工业株式会社 2020-02-21 CN disclosed
US-20170355678-A1 C-Met Modulators and Methods of Use EXELIXIS INC (US) 2017-12-14 US disclosed
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 US disclosed
CN-104418678-B A kind of method of synthetic N-alkyl sulfonamide derivatives NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2016-05-18 CN disclosed
US-8178532-B2 c-Met modulators and method of use EXELIXIS, INC. (US) 2012-05-15 US disclosed
US-20120022065-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2012-01-26 US disclosed
US-8067436-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2011-11-29 US disclosed
US-20110077233-A1 C-Met Modulators and Method of Use EXELIXIS, INC. (US) 2011-03-31 US disclosed
US-7579473-B2 N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death EXELIXIS, INC. (US) 2009-08-25 US disclosed
US-20090170896-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2009-07-02 US disclosed
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE EXELIXIS, INC (US) 2009-04-23 US disclosed
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-10-18 US disclosed
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE EXELIXIS, INC. (US) 2007-09-27 US disclosed
US-20070054928-A1 c-Met modulators and methods of use EXELIXIS, INC. (US) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331860-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET CA12 2958/4885CA9 1962/4885L3MBTL1 2294/4885
US-20070054928-A1 c-Met modulators and methods of use FLT4, FLT1, MET CA12 2958/4885CA9 1962/4885L3MBTL1 2294/4885
US-20120022065-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 CA12 2755/4885CA9 2229/4885L3MBTL1 2747/4885
US-20170355678-A1 C-Met Modulators and Methods of Use FLT4, FLT1, MET CA12 2958/4885CA9 1962/4885L3MBTL1 2294/4885
US-20210253530-A9 C-MET MODULATORS AND METHODS OF USE FLT4, FLT1, MET CA12 2958/4885CA9 1962/4885L3MBTL1 2294/4885
US-20090170896-A1 c-Met modulators and methods of use FLT4, MET, FLT1 CA12 2747/4885CA9 2270/4885L3MBTL1 2564/4885
US-20070225307-A1 C-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 CA12 2755/4885CA9 2229/4885L3MBTL1 2747/4885
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 CA12 2755/4885CA9 2229/4885L3MBTL1 2747/4885
US-20070244116-A1 c-MET MODULATORS AND METHOD OF USE FLT4, MET, FLT1 CA12 2755/4885CA9 2229/4885L3MBTL1 2747/4885
US-11124482-B2 C-met modulators and methods of use FLT4, FLT1, MET CA12 2958/4885CA9 1962/4885L3MBTL1 2294/4885
US-20090105299-A1 c-MET MODULATORS AND METHODS OF USE FLT4, MET, FLT1 CA12 2747/4885CA9 2270/4885L3MBTL1 2564/4885
US-20110077233-A1 C-Met Modulators and Method of Use FLT4, MET, FLT1 CA12 2755/4885CA9 2229/4885L3MBTL1 2747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.